key: cord-321402-7a04kx5n authors: Rezakhani, Leila; Kelishadrokhi, Ali Fatahian; Soleimanizadeh, Arghavan; rahmati, Shima title: Mesenchymal stem cell (MSC)-derived exosomes as a cell-free therapy for Patients Infected with COVID-19: Real Opportunities and Range of Promises date: 2020-11-12 journal: Chem Phys Lipids DOI: 10.1016/j.chemphyslip.2020.105009 sha: doc_id: 321402 cord_uid: 7a04kx5n There are no commercially available effective antiviral medications or vaccines to deal with novel coronavirus disease (COVID-19). Hence there is a substantial unmet medical need for new and efficacious treatment options for COVID-19. Most COVID-19 deaths result from acute respiratory distress syndrome (ARDS). This virus induces excessive and aberrant inflammation so it is important to control the inflammation as soon as possible. To date, results of numerous studies have been shown that mesenchymal stem cells and their derivatives can suppress inflammation. Exosomes function as intercellular communication vehicles to transfer bioactive molecules (based on their origins), between cells. In this review, the recent exosome-based clinical trials for the treatment of COVID-19 are presented. Potential therapy may include the following items: First, using mesenchymal stem cells secretome. Second, incorporating specific miRNAs and mRNAs into exosomes and last, using exosomes as carriers to deliver drugs. contact. Through sneeze and cough, droplet sprays can directly contaminate people, or inhaling airborne microscopic aerosol can also infect people with this virus (2, 3) . Most patients have mild respiratory tract infection, with fever and cough. However, in some people, infection with Covid-19 may be asymptomatic, which may be involved in the spread of the virus. More than half of the patients are asymptomatic with CT and laboratory findings disorders (4) . Elderly patients were stated to have a more serious symptom with the ICU admission ratio compare to younger patients (5) . Obesity and underlying diseases such as diabetes can lead to young patients being admitted to the ICU (6, 7). However, effective antiviral medications nor vaccines are not commercially available to deal with this emergency. Once infected, the patient mainly relies on his immune system to resist SARS-CoV-2, with the supportive treatment given if complications occur (7) (8) (9) . SARS-CoV-2 can enter the cell through binding to angiotensin I converting enzyme 2 receptor (ACE2) by its spike protein receptor-binding domain (RBD). This virus induces excessive and aberrant host immune responses which are often accompanied by overproduction of pro-inflammatory cytokines including IL-2, IL-6, IL-7, GSCF, IP10, MCP1, MIP1A, and TNF (10) . By targeting lung tissue, these cytokines induce pulmonary edema and subsequent acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) (11) . Therefore, introducing appropriate therapeutic approaches for both cytokine storm suppression and lung repair functions are urgently needed. have several features that make them a potential candidate for COVID-19 treatment: these cells can modulate immune responses, reduce inflammation, and thus protecting alveolar epithelial cells during ALI and ARDS. Also, due to the presence of specific J o u r n a l P r e -p r o o f cytokines, MSCs can suppress viral infection (12) . To date, several studies have proposed MSCs for COVID-19 pneumonia treatment (11, (13) (14) (15) . In a research by Shu and his colleges, it has been shown that intravenous transplantation of hUC-MSCs is an effective and safe method for the treatment of severe COVID-19. Their results showed that, the time to clinical improvement in the hUCMSC treatment group, was shorter than that of the control group. In addition, the 28-day mortality rate in the hUC-MSC treatment group was 0, compared with 10.34% in the control group (16) . Few studies have paid attention to stem cell secretome like extracellular vesicles (EVs) (17) . In a study by Sengupta et al. exosomes derived from allogeneic bone marrow mesenchymal stem cells (ExoFlo) were used for treatment of SARS-CoV-2 PCR positive patients. They received a single 15 mL intravenous dose of ExoFlo, and safety and efficacy were evaluated 1-14 day posttreatment. The results showed a survival rate of 83%. 71% of the patients recovered, 13% remained seriously ill though stable and, 16% expired for reasons not related to the treatment. Furthermore laboratory results showed significant improvements in neutrophil and CD3+, CD4+ and CD8+ lymphocyte numbers, with a decline in C-reactive protein (CRP) and Ferritin (18) Exosomes are one of the extracellular vesicles enclosed by a lipid bilayer. Based on their primary sources, exosomes carry complex cargo including bioactive molecules such as nucleic acids, microRNA, lipids, and proteins, which are transmitted to adjacent and distant cells and thus alter the fate of the recipient cell (19) .Various methods for the extraction of exosomes have been developed, such as centrifugation series followed by high-speed ultracentrifugation. In this process, the separation of exosomes is based on the mass, shape and size of the sequential separations. One of the advantages of this approach is reduced costs and lower chances of contamination, but it cannot differentiate between exosomes and other small vesicles or large J o u r n a l P r e -p r o o f protein aggregates (20) . Another method is gradient ultracentrifugation which provides a high yield of isolated exosomes that retain their functions, but this approach has a low specificity compared to size exclusion chromatography (21) . Size and protein markers are the most important characteristics for exosome characterization. Exosomes can be detected using scanning electron microscopy (SEM), transmission electron microscopy (TEM), and nanoparticle tracking analysis (NTA) (22) . Furthermore biochemical characterization can reveal common characteristic of exosomal proteins (23) . The proteins which are most abundant are CD9, CD63, CD81, and CD82), MHC molecules, 14-3-3 proteins, heat shock proteins (HSPs), and Tsg101 (24). As we reviewed recently (25, 26) , due to their unique ability to deliver and exchange intracellular chemical messages and interact with receiver cells, exosomes have been increasingly applied in the treatment of several diseases ( fig. 1 ). J o u r n a l P r e -p r o o f Figure 1 : Several exosome therapeutic application in various disease (25) Up to now, (9/03/2020) 7 clinical trials using exosome to treat COVID 19 are underway (Table 1) . Researches have shown that the potential of exosomes for COVID 19 treatment can be divided into three general categories. First, using exosomal particles secreted by different sources of mesenchymal stem cells instead of cell therapy. Second, incorporating specific miRNAs and mRNAs into exosomes a last, using exosomes as carriers to deliver drugs to treat COVID-19. However, it is now clear that MSCs act via a paracrine mechanism (25) . MSC-secretome consists of both extracellular vesicles and several soluble proteins, cytokines, chemokines, and growth factors (27) . This secretome can interact with the target cells and modify the recipient cell's fate by endogenous stem cells activation, apoptosis suppression, regulating the inflammatory response, fibrosis reduction, and mediating the chemoattraction (28) . Several studies (29) (30) (31) have shown that the therapeutic effects of MSCs secretome such as antiinflammatory, regenerative, immunomodulatory pro-angiogenic, and anti-protease properties (32) , are similar to the MSCs of origin. Therefore, this conditioned medium harvested from MSCs, can be considered as a promising cell-free therapeutic tool in the treatment of lung diseases. The results of a research (13) showed that the intravenous infusion of MSCs resulted in increased peripheral lymphocytes, overactivation of some types of T cells, and the reduction of the C-reactive protein. In preclinical ARDS, the efficacy of MSCs secretome is obvious in both in vivo and ex vivo, for instance, secretome distributed through both lungs after intravenous injection, with the high stability in the blood flow (30) . Notably, the use of exosomes in therapy has more benefits than MSCs. Exosomes are smaller and less complex than MSCs, thus the production and their storage J o u r n a l P r e -p r o o f are more feasible. In addition, they do not have the ability to self-replicate, so the risk of endogenous tumor formation is reduced. Besides, they show low immunogenicity effect and low emboli formation after intravenous injection as a result they are safer than routine MSCs, finally the cost of using MSCs secretome will be much lower than monoclonal antibody therapy (25) , which is so important in a pandemic treatment. For the first time, Bari The mechanism of viral replication in the infected cell is the use of a nucleic acid and protein synthesis system (34) . Protein synthesis in animal cells is regulated by microRNA or miRNA (mRNA-inhibiting RNA). miRNAs are a class of the small non-coding RNAs that regulate the mRNA translation of target genes by interaction with 3´ untranslated region of relating mRNA (35) . Since viral protein synthesis occurs in the host cell, this regulatory function of miRNAs can be used against viral diseases. Using miRNAs in this purpose requires perfect or near-perfect J o u r n a l P r e -p r o o f matches with the mRNA of the viral genome (gRNA) or parts of its genome that is protein-coding. This binding, cause cleavage and degradation of the target gene (36) . Therefore, in order to minimize the side effects, it is important to select a sequence of miRNAs that specifically bind to the virus genome. Complementary sequences to the human genome can including non-specific gene silencing (37) . There are several powerful programs to identify and predict gene targets of miRNAs, such as MirTarget, MiRanda, TargetScan and, PicTar II (38) . Ivashchenko and colleagues (39) , decided to identify human miRNAs that affect the expression of SARS-CoV-2 coronavirus genomes. Their goal was to design a set of miRNAs that would specifically bind to the coronavirus genome to destroy it, without any side effects on human gene expression which may have the potential to be used as a new approach in coronavirus treatment. Using MirTarget, they identified miR-5197-3p out of the 2565 miRNAs that had the greatest potential to interaction with the gRNA of SARS-CoV-2, without having target genes among the 17508 human coding genes. A possible explanation for the fact that SARS-CoV-2 infection is less frequently observed in children aged less than 15 years compared to adults over 60 years is that the expression of piwiinteracting RNA (pi-RNA) and miRNA is Age-Dependent phenomena, in fact pi-RNA expression is decreased with age, while miRNA expression is increased. It seems that during ontogenesis the expression of one or more pi-RNAs that can bind to the viral gRNA decreases. Likewise, the concentration of miRNAs capable of binding to the gRNA and expressed in the early stages of ontogenesis may decrease, and the virus begins to multiply (40, 41) ., In long-distance cell to cell communication, exosomes are of great importance because they can enter the circulation and pass through additional biological barriers. More recent evidence J o u r n a l P r e -p r o o f indicates that they can carry rich cargo between cells. Due to the specific structure of the exosomes various drugs can be inserted into them so they can be used in a variety of diseases as drug delivery systems (42) . In addition, in personalized medicine, exosomes can be separated from the patient's plasma, then filled with the exogenous drug of interest, and finally given back to the same patient (43) . The immunomodulatory cargo of MSCs exosomes combined with the anti-viral drugs makes them a novel intervention tool for the treatment of the disease (44) . Remdesivir antiviral drug, which is prescribed for the treatment of patients with Covid-19 (9, 45) , can be load in to the exosome. However, in the case of COVID-19, more scrutiny is essential to have a full understanding of their safety, specificity, proficiency, and delivery mechanisms of antiretroviral drugs to target tissues. To overcome the pandemic of COVID-19, we need to develop a multi-directional strategy to minimize its prevalence. In this infection, severe cytokine storm is the main contributor to organ damage, MSCs not only suppress the cytokine storm but also facilitate endogenous regenerative mechanisms due to their strong immunomodulatory capability (46) .In addition to MSCs, their derivatives including exosomes have earned considerable interest as a therapeutic technique. Exosome-based therapy is an attractive strategy for achieving the therapeutic benefits of MSCs without the complications and difficulties of the cells to the patients. In particular, the possible use of exosomes in preclinical models to alleviate ARDS is well known (47) . This technique can be used as an effective therapy for the delivery of different synthetic and biological molecules in cellular therapy of various diseases. Indeed, these cells can be considered as potent drug stores releasing biologically active substances. Furthermore in comparison with other treatments such as monoclonal antibody therapy, the costs of MSC-secretome seem probably J o u r n a l P r e -p r o o f lower which is important in treating a pandemic (48) . Despite the potential of MSC-derived exosomes for treatment of SARS-CoV-2, the use of exosomes for any purpose in SARS-CoV-2, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs are currently pending the generation of appropriate manufacturing and quality control provisions (49) .Current clinical trials highlight the potential benefits of stem cell secretome therapies for COVID-19 patients. However, further studies are therefore important to clarify the safety and effectiveness of these therapies and their long-term outcomes. The authors declare no competing interests. Please check the following as appropriate:  All authors have participated in (a) conception and design, or analysis and interpretation of the data; (b) drafting the article or revising it critically for important intellectual content; and (c) approval of the final version.  This manuscript has not been submitted to, nor is under review at, another journal or other publishing venue. Stem cell-based therapy for coronavirus disease 2019 A novel coronavirus from patients with pneumonia in China The coronavirus pandemic and aerosols: Does COVID-19 transmit via expiratory particles? Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Obesity could shift severe COVID-19 disease to younger ages Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission A pneumonia outbreak associated with a new coronavirus of probable bat origin Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus Mesenchymal stem cells and management of COVID-19 pneumonia. Medicine in drug discovery Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019 Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia Mesenchymal stem cell therapy for COVID-19: present or future. Stem cell reviews and reports Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19 Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells and Development Extracellular vesicles: biology and emerging therapeutic opportunities Exosomes: composition, biogenesis and function Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds Characterisation of exosomes derived from human cells by nanoparticle tracking analysis and scanning electron microscopy Characterization of exosomelike vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense Standardization of sample collection, isolation and analysis methods in extracellular vesicle research An overview of current knowledge in biological functions and potential theragnostic applications of exosomes. Chemistry and physics of lipids Isolation and characterization of crab hemolymph exosomes and its effects on Mesenchymal stem/stromal cell extracellular vesicles: From active principle to next generation drug delivery system Towards therapeutic delivery of extracellular vesicles: strategies for in vivo tracking and biodistribution analysis Mesenchymal stem/stromal cell secretome for lung regeneration: The long way through "pharmaceuticalization" for the best formulation Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use Mesenchymal stromal cell secretome: influencing therapeutic potential by cellular pre-conditioning Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem cells translational medicine Mesenchymal stem/stromal cell secretome for lung regeneration: The long way through "pharmaceuticalization" for the best formulation Translational control in virus-infected cells. Cold Spring Harbor perspectives in biology A combined panel of circulating microRNA as a diagnostic tool for detection of the non-small cell lung cancer MicroRNA-directed cleavage of HOXB8 mRNA Subcellular fate and off-target effects of siRNA, shRNA, and miRNA A guide through present computational approaches for the identification of mammalian microRNA targets How miRNAs can protect humans from coronaviruses COVID-19 Importance of miRNA stability and alternative primary miRNA isoforms in gene regulation during Drosophila development Are children less susceptible to COVID-19 Extracellular vesicles for drug delivery. Advanced drug delivery reviews Emerging roles for extracellular vesicles in tissue engineering and regenerative medicine Mesenchymal Stem Cell Derived Exosomes: a Nano Platform for Therapeutics and Drug Delivery in Combating COVID-19 Compassionate use of remdesivir for patients with severe Covid-19 Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia An investigation of topics and trends of tracheal replacement studies using co-occurrence analysis Mesenchymal stem cells: time to change the name! Stem cells translational medicine International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19 The authors acknowledge the Cellular and Molecular Research Center of Kurdistan University of Medical Sciences for supporting our team. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.